Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study
المؤلفون المشاركون
Bosnyák, Edit
Herceg, Mihály
Pál, Endre
Aschermann, Zsuzsanna
Janszky, József
Késmárki, Ildikó
Komoly, Sámuel
Karádi, Kázmér
Dóczi, Tamás
Nagy, Ferenc
Kovács, Norbert
المصدر
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-08-26
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
The aim of this study was to compare the efficacy of the branded and a generic extended-release ropinirole formulation in the treatment of advanced Parkinson’s disease (PD).
Of 22 enrolled patients 21 completed the study.
A rater blinded to treatment evaluated Unified Parkinson’s Disease Rating Scale, Fahn-Tolosa-Marin Tremor Rating Scale, Nonmotor Symptoms Assessment Scale, and a structured questionnaire on ropinirole side effects.
Besides, the patients self-administered EQ-5D, Parkinson’s Disease Sleep Scale (PDSS-2), and Beck Depression Inventories.
Branded and generic ropinirole treatment achieved similar scores on all tests measuring severity of motor symptoms (primary endpoint, UPDRS-III: 27.0 versus 28.0 points, P=0.505).
Based on patient diaries, the lengths of “good time periods” were comparable (10.5 and 10.0 hours for branded and generic ropinirole, resp., P=0.670).
However, generic ropinirole therapy achieved almost 3.0 hours shorter on time without dyskinesia (6.5 versus.
9.5 hours, P<0.05) and 2.5 hours longer on time with slight dyskinesia (3.5 versus.
1.0 hours, P<0.05) than the branded ropinirole did.
Except for gastrointestinal problems, nonmotor symptoms were similarly controlled.
Patients did not prefer either formulation.
Although this study has to be interpreted with limitations, it demonstrated that both generic and branded ropinirole administration can achieve similar control on most symptoms of PD.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Bosnyák, Edit& Herceg, Mihály& Pál, Endre& Aschermann, Zsuzsanna& Janszky, József& Késmárki, Ildikó…[et al.]. 2014. Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study. Parkinson’s Disease،Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1047199
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Bosnyák, Edit…[et al.]. Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study. Parkinson’s Disease No. 2014 (2014), pp.1-7.
https://search.emarefa.net/detail/BIM-1047199
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Bosnyák, Edit& Herceg, Mihály& Pál, Endre& Aschermann, Zsuzsanna& Janszky, József& Késmárki, Ildikó…[et al.]. Are Branded and Generic Extended-Release Ropinirole Formulations Equally Efficacious? A Rater-Blinded, Switch-Over, Multicenter Study. Parkinson’s Disease. 2014. Vol. 2014, no. 2014, pp.1-7.
https://search.emarefa.net/detail/BIM-1047199
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1047199
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر